
    
      This Phase 4, prospective, multi-center, open-label study will evaluate safety, platelet
      count, and subject reported medication satisfaction in adult subjects with chronic ITP after
      switching to avatrombopag from eltrombopag or romiplostim. At least 100 subjects will be
      enrolled, 50 (±10) who have received eltrombopag and 50 (±10) who have received romiplostim
      for at least 90 days prior to study entry.
    
  